Diffuse Large B Cell Lymphoma

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	RG6026 Sensitive: B - Late Trials Roche Press Release - 3 weeks (New B) RG6026 Sensitive : B Roche Press Release - 3wk	RG6026 Sensitive: B - Late Trials Roche Press Release - 3 weeks RG6026 Sensitive : B Roche Press Release - 3 weeks - (New B)
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1	tisagenlecleucel-T Sensitive: A1 - Approval tisagenlecleucel-T Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab + polatuzumab vedotin-piiq Sensitive: A1 - Approval rituximab + polatuzumab vedotin-piiq Sensitive : A1	rituximab + polatuzumab vedotin-piiq Sensitive: A1 - Approval rituximab + polatuzumab vedotin-piiq Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lenalidomide + tafasitamab-cxix Sensitive: A1 - Approval lenalidomide + tafasitamab-cxix Sensitive : A1	lenalidomide + tafasitamab-cxix Sensitive: A1 - Approval lenalidomide + tafasitamab-cxix Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	polatuzumab vedotin-piiq Sensitive: A1 - Approval polatuzumab vedotin-piiq Sensitive : A1	polatuzumab vedotin-piiq Sensitive: A1 - Approval polatuzumab vedotin-piiq Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	loncastuximab tesirine Sensitive: A1 - Approval loncastuximab tesirine Sensitive : A1	loncastuximab tesirine Sensitive: A1 - Approval loncastuximab tesirine Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	selinexor Sensitive: A1 - Approval selinexor Sensitive : A1	selinexor Sensitive: A1 - Approval selinexor Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab/hyaluronidase Sensitive: A1 - Approval rituximab / hyaluronidase Sensitive : A1	rituximab/hyaluronidase Sensitive: A1 - Approval rituximab / hyaluronidase Sensitive : A1
CD20 positive	Diffuse Large B Cell Lymphoma	CD20 positive	Diffuse Large B Cell Lymphoma	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TNFRSF8 positive	Diffuse Large B Cell Lymphoma	TNFRSF8 positive	Diffuse Large B Cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	MINE Sensitive: A2 - Guideline MINE Sensitive : A2	MINE Sensitive: A2 - Guideline MINE Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	R-GemOx Sensitive: A2 - Guideline R-GemOx Sensitive : A2	R-GemOx Sensitive: A2 - Guideline R-GemOx Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	GemOx Sensitive: A2 - Guideline GemOx Sensitive : A2	GemOx Sensitive: A2 - Guideline GemOx Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	ESHAP Sensitive: A2 - Guideline ESHAP Sensitive : A2	ESHAP Sensitive: A2 - Guideline ESHAP Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	ICE Sensitive: A2 - Guideline ICE Sensitive : A2	ICE Sensitive: A2 - Guideline ICE Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	RICE Sensitive: A2 - Guideline RICE Sensitive : A2	RICE Sensitive: A2 - Guideline RICE Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	carboplatin + rituximab + gemcitabine + dexamethasone Sensitive: A2 - Guideline carboplatin + rituximab + gemcitabine + dexamethasone Sensitive : A2	carboplatin + rituximab + gemcitabine + dexamethasone Sensitive: A2 - Guideline carboplatin + rituximab + gemcitabine + dexamethasone Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	carboplatin + gemcitabine + dexamethasone Sensitive: A2 - Guideline carboplatin + gemcitabine + dexamethasone Sensitive : A2	carboplatin + gemcitabine + dexamethasone Sensitive: A2 - Guideline carboplatin + gemcitabine + dexamethasone Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	GDP Sensitive: A2 - Guideline GDP Sensitive : A2	GDP Sensitive: A2 - Guideline GDP Sensitive : A2

Diffuse Large B Cell Lymphoma

Associations(309)

Associations
(309)